Zymeworks (ZYME) Total Current Liabilities (2021 - 2026)
Zymeworks' (ZYME) quarterly Total Current Liabilities came in at $35.6 million in Q1 2026, down 45.24% year-on-year from $65.1 million in Q1 2025, and down 15.76% quarter-over-quarter from $42.3 million in Q4 2025.
Zymeworks (ZYME) Total Current Liabilities (2021 - 2026) Analysis & Trends
Zymeworks has disclosed Total Current Liabilities across 6 years of filings, most recently posting $35.6 million for Q1 2026.
- Total Current Liabilities for Q1 2026 came in at $35.6 million, down 45.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $35.6 million (down 45.24% YoY), and the FY2025 annual result was $42.3 million, down 52.07% from the prior year.
- Total Current Liabilities came in at $35.6 million for Q1 2026 at Zymeworks, down from $42.3 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $95.6 million in Q4 2022 to a low of $35.6 million in Q1 2026.
- The 5-year median for Total Current Liabilities is $57.7 million (2022), against an average of $63.3 million.
- Across the five-year window, Total Current Liabilities surged 58.34% in 2024 and tumbled 52.07% in 2025, its largest moves.
- Zymeworks' Total Current Liabilities stood at $95.6 million in 2022, then slumped by 41.69% to $55.8 million in 2023, then surged by 58.34% to $88.3 million in 2024, then slumped by 52.07% to $42.3 million in 2025, then dropped by 15.76% to $35.6 million in 2026.
- The last three Total Current Liabilities figures came in at $35.6 million (Q1 2026), $42.3 million (Q4 2025), and $42.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1.70 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 636.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 13.42 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 3.88 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 72.86 Mn |
| 10 | Zymeworks | 1.73 Bn | 1.36 Bn | - | 35.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.65 Mn |
| Dec 31, 2025 | 42.32 Mn |
| Sep 30, 2025 | 42.04 Mn |
| Jun 30, 2025 | 38.50 Mn |
| Mar 31, 2025 | 65.10 Mn |
| Dec 31, 2024 | 88.29 Mn |
| Sep 30, 2024 | 83.91 Mn |
| Jun 30, 2024 | 54.71 Mn |
| Mar 31, 2024 | 56.89 Mn |
| Dec 31, 2023 | 55.76 Mn |
| Sep 30, 2023 | 72.85 Mn |
| Jun 30, 2023 | 93.55 Mn |
| Mar 31, 2023 | 67.32 Mn |
| Dec 31, 2022 | 95.63 Mn |
| Sep 30, 2022 | 57.71 Mn |
| Dec 31, 2021 | 71.85 Mn |